A panel of doctors lauded the recent approval of CASGEVY, a gene therapy for sickle-cell disease, but called for advocacy to make the treatment affordable, especially for people on Medicaid. The panel ...
For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
UrbanGeekz on MSN
How gene therapy could end sickle cell disease
For generations, Sickle Cell Disease has been a devastating illness affecting millions of people around the world, ...
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY ® ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment - CASGEVY is the only genetic therapy approved ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with NHS England for eligible sickle cell disease or SCD ...
Tuesday, the FDA approved CRISPR Therapeutics AG’s (NASDAQ:CRSP)/Vertex Pharmaceutical Incorporated’s (NASDAQ:VRTX) Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy ...
The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results